Skip to main content
SpringerLink
Log in

New Therapeutic Strategies

  • Chapter
  • First Online:
Inflammatory Bowel Disease Nursing Manual

  • 1487 Accesses

Abstract

Despite major advances in the management of inflammatory bowel diseases (IBD) a considerable proportion of patients remain refractory to conventional and currently licenced biologic therapies. This chapter summarises the immunological pathways that drive intestinal inflammation in Crohn’s disease (CD) and ulcerative colitis (UC) and then reviews emerging drugs targeting different components of these pathways. These include biological agents against integrins and cytokines, small molecules; anti-sense oligonucleotides and cell based therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

CCR9:

Chemokine receptor 9

CD:

Crohn’s disease

DAI:

Disease activity index

EMA:

European Medicines Agency

FMT:

Faecal microbiota transplantation

FDA:

Food and Drug Administration

HSCT:

Haematopoietic stem cell transplan-tation

IBD:

Inflammatory bowel disease

IFN-γ:

Interferon γ

IL:

Interleukin

ICAM1:

Intracellular adhesion molecule-1

JAK:

Janus kinase

MSCs:

Mesenchymal stem cells

Treg cells:

Regulatory T cells

STAT:

Signal transducer and activator of transcription

S1P:

Sphingosine 1-phosphate

Th cells:

T-helper cells

TDM:

Therapeutic drug monitoring

TNF-α:

Tumour necrosis factor-α

UC:

Ulcerative colitis

References

  • Abraham C, Dulai PS, Vermeire S, Sandborn WJ (2017) Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology 152(2):374–388.e4

    Article  CAS  Google Scholar 

  • Ala A, Dhillon AP, Hodgson HJ (2003) Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. Int J Exp Pathol 84(1):1–16

    Article  CAS  Google Scholar 

  • Baeyens A, Fang V, Chen C, Schwab SR (2015) Exit strategies: S1P signaling and T cell migration. Trends Immunol 36(12):778–787

    Article  CAS  Google Scholar 

  • Boirivant M, Pallone F, Di Giacinto C, Fina D, Monteleone I, Marinaro M et al (2006) Inhibition of Smad7 with a specific antisense oligonucleotide facilitates. Gastroenterology 131(6):1786–1798

    Article  CAS  Google Scholar 

  • Chirila TV, Rakoczy PE, Garrett KL, Lou X, Constable IJ (2002) The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 23(2):321–342

    Article  CAS  Google Scholar 

  • Chiu H-Y, Chen C-H, Wu M-S, Cheng Y-P, Tsai T-F (2013) The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 169(6):1295–1303

    Article  CAS  Google Scholar 

  • D’Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H et al (2015) A phase II study of laquinimod in Crohn’s disease. Gut 64(8):1227–1235

    Article  Google Scholar 

  • Danese S (2012) New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 61(6):918–932

    Article  CAS  Google Scholar 

  • Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G et al (2016) 764 results of Andante, a randomized clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn’s disease who are anti-TNF inadequate responders. Gastroenterology 150(4):S155

    Article  Google Scholar 

  • Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y et al (2012) Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn’s disease. Gastroenterology 143(5):1207–1217.e1

    Article  CAS  Google Scholar 

  • van Deventer SJH, Tami JA, Wedel MK (2004) A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53(11):1646–1651

    Article  Google Scholar 

  • van Deventer SJH, Wedel MK, Baker BF, Xia S, Chuang E, Miner PBJ (2006) A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23(10):1415–1425

    Article  Google Scholar 

  • Dudakov JA, Hanash AM, van den Brink MRM (2015) Interleukin-22: immunobiology and pathology. Annu Rev Immunol 33:747–785

    Article  CAS  Google Scholar 

  • Duijvestein M, Vos ACW, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW et al (2010) Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut 59(12):1662–1669

    Article  Google Scholar 

  • Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710

    Article  CAS  Google Scholar 

  • Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375(20):1946–1960

    Article  CAS  Google Scholar 

  • Feagan BG, Sandborn WJ, D’Haens G, Panes J, Kaser A, Ferrante M et al (2017) Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389(10080):1699–1709

    Article  CAS  Google Scholar 

  • Francis G, Kappos L, O’Connor P, Collins W, Tang D, Mercier F et al (2014) Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler Houndmills Basingstoke Engl 20(4):471–480

    Article  CAS  Google Scholar 

  • Ghosh S, Panaccione R (2010) Anti-adhesion molecule therapy for inflammatory bowel disease. Ther Adv Gastroenterol 3(4):239–258

    Article  CAS  Google Scholar 

  • Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F (2016) Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: a case series. United European Gastroenterol J 4(1):97–104

    Article  CAS  Google Scholar 

  • Hawkey CJ, Hommes DW (2017) Is stem cell therapy ready for prime time in treatment of inflammatory bowel diseases? Gastroenterology 152(2):389–397.e2

    Article  Google Scholar 

  • Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E et al (2015) Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 314(23):2524–2534

    Article  CAS  Google Scholar 

  • Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S (2016) Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15(3):173–183

    Article  CAS  Google Scholar 

  • Li C, Kuemmerle JF (2014) Mechanisms that mediate the development of fibrosis in patients with Crohn’s disease. Inflamm Bowel Dis 20(7):1250–1258

    Article  Google Scholar 

  • Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G et al (2017) Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol 2(6):399–406

    Article  Google Scholar 

  • Miner P, Wedel M, Bane B, Bradley J (2004) An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 19(3):281–286

    Article  CAS  Google Scholar 

  • Miner PBJ, Wedel MK, Xia S, Baker BF (2006a) Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 23(10):1403–1413

    Article  CAS  Google Scholar 

  • Miner PBJ, Geary RS, Matson J, Chuang E, Xia S, Baker BF et al (2006b) Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther 23(10):1427–1434

    Article  CAS  Google Scholar 

  • Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT (2001) Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 108(4):601–609

    Article  CAS  Google Scholar 

  • Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F et al (2015) Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 372(12):1104–1113

    Article  CAS  Google Scholar 

  • Okamoto R, Watanabe M (2016) Investigating cell therapy for inflammatory bowel disease. Expert Opin Biol Ther 16(8):1015–1023

    Article  CAS  Google Scholar 

  • Otero-Vinas M, Falanga V (2016) Mesenchymal stem cells in chronic wounds: the spectrum from basic to advanced therapy. Adv Wound Care 5(4):149–163

    Article  Google Scholar 

  • Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC et al (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388(10051):1281–1290

    Article  Google Scholar 

  • Paramsothy S, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D et al (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389(10075):1218–1228

    Article  Google Scholar 

  • Sandborn WJ (2016) Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. Oral presentation presented at: ECCO; Amsterdam

    Google Scholar 

  • Sandborn WJ, Panés J (2017) Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. Oral presentation presented at: ECCO; Barcelona

    Article  Google Scholar 

  • Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367(7):616–624

    Article  CAS  Google Scholar 

  • Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721

    Article  CAS  Google Scholar 

  • Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W (2014) A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol 12(9):1485–1493 e2

    Article  CAS  Google Scholar 

  • Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, Vermeire S, Hanauer SB et al (2016) Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 374(18):1754–1762

    Article  CAS  Google Scholar 

  • Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M et al (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122(1):44–54

    Article  Google Scholar 

  • Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L, Cooper AM et al (2015) IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 21(7):719–729

    Article  CAS  Google Scholar 

  • Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615–2623

    Article  CAS  Google Scholar 

  • Vegter S, Tolley K, Wilson Waterworth T, Jones H, Jones S, Jewell D (2013) Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther 38(3):284–293

    Article  CAS  Google Scholar 

  • Vermeire S, O’Byrne S, Keir M, Williams M, Lu TT, Mansfield JC et al (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 384(9940):309–318

    Article  CAS  Google Scholar 

  • Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X et al (2017) Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 389(10066):266–275

    Article  CAS  Google Scholar 

  • de Vries L, Wildenberg M, de Jonge W, D’Haens G (2017) The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis 11(7):885–893

    Article  Google Scholar 

  • William S, Christopher G, Daphne C, Yinghua L, Paul P, Stephen H et al (2017) PD-012 endoscopic healing in the ustekinumab phase 3 UNITI/IMUNITI Crohn’s disease program and relationship of clinical outcomes to baseline ulceration status. Inflamm Bowel Dis. 23:S9. Available from http://journals.lww.com/ibdjournal/Fulltext/2017/02001/PD_012_Endoscopic_Healing_in_the_Ustekinumab_Phase.26.aspx.

  • Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL et al (2002) Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut 51(1):30–36

    Article  CAS  Google Scholar 

  • Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E (2007) A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol 5(2):215–220

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Barts Health NHS Trust, London, UK

    Klaartje Kok, Ana Ibarra & James Lindsay

  2. Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK

    Klaartje Kok & James Lindsay

Authors
  1. Klaartje Kok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Ibarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Lindsay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Lindsay .

Editor information

Editors and Affiliations

  1. DRK Kliniken Berlin Westend, Department of Gastroenterology, Berlin, Germany

    Andreas Sturm

  2. Gastroenterology Level 5, John Radcliffe Hospital, Oxford, UK

    Lydia White

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kok, K., Ibarra, A., Lindsay, J. (2019). New Therapeutic Strategies. In: Sturm, A., White, L. (eds) Inflammatory Bowel Disease Nursing Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-75022-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75022-4_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75021-7

  • Online ISBN: 978-3-319-75022-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation